[[ type === 'moc' ? 'MARKET ON CLOSE' : 'FREE WEBINAR' ]]
[[ timeLabel ]] WATCH LIVE:
Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Barchart Premier: The most comprehensive method for keeping track of all your investments. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Allogene Therapeutics Inc (ALLO)

Allogene Therapeutics Inc (ALLO)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]] ([[ financialData.relativeStrengthDirection14d ]]) ([[ financialData.highPercent1y ]]) ([[ financialData.lowPercent1y ]])
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 690,310
  • Shares Outstanding, K 345,155
  • Annual Sales, $ 0 K
  • Annual Income, $ -190,890 K
  • EBIT $ -190 M
  • EBITDA $ -182 M
  • 60-Month Beta 0.46
  • Price/Sales N/A
  • Price/Cash Flow N/A
  • Price/Book 1.72

Options Overview Details

View History
  • Implied Volatility 67.81% (+3.95%)
  • Historical Volatility 107.35%
  • IV Percentile 1%
  • IV Rank 0.62%
  • IV High 700.73% on 11/17/25
  • IV Low 63.86% on 05/21/26
  • Expected Move (DTE 26) 0.30 (14.88%)
  • Put/Call Vol Ratio 0.04
  • Today's Volume 410
  • Volume Avg (30-Day) 818
  • Put/Call OI Ratio 0.13
  • Today's Open Interest 16,237
  • Open Int (30-Day) 26,163
  • Expected Range 1.70 to 2.30

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 16 analysts offering recommendations.
Earnings Estimates - Current Qtr 06/30/26
See More
  • Average Estimate $-0.16
  • Number of Estimates 5
  • High Estimate $-0.13
  • Low Estimate $-0.20
  • Prior Year $-0.23
  • Growth Rate Est. (year over year) +30.43%

Price Performance

See More
Period Period Low Period High Performance
1-Month
1.84 +8.70%
on 05/21/26
2.41 -17.01%
on 04/23/26
-0.39 (-16.32%)
since 04/22/26
3-Month
1.84 +8.70%
on 05/21/26
4.46 -55.16%
on 04/13/26
-0.05 (-2.44%)
since 02/20/26
52-Week
0.98 +103.21%
on 08/07/25
4.46 -55.16%
on 04/13/26
+0.91 (+83.49%)
since 05/22/25

Most Recent Stories

More News
Allogene Therapeutics Q1 Earnings Call Highlights

Allogene Therapeutics (NASDAQ:ALLO) said its first quarter of 2026 was marked by early clinical progress for its lead allogeneic CAR-T programs and a strengthened cash position following an April financing.On...

ALLO : 2.00 (+2.04%)
Allogene Therapeutics: Q1 Earnings Snapshot

Allogene Therapeutics: Q1 Earnings Snapshot

ALLO : 2.00 (+2.04%)
Allogene Therapeutics Reports First Quarter 2026 Financial Results and Business Update

Planned Interim Futility Analysis from Pivotal Phase 2 ALPHA3 Trial Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatient, MRD-Guided Consolidation Therapy in 1L Large B-cell Lymphoma...

ALLO : 2.00 (+2.04%)
Can Allogene's Cash Runway Outlast Its Clinical Timeline This Time?

Barchart Research What to Expect from ALLO Earnings ALLO Generated May 12, 2026 Current Price $2.30 EPS Estimate $$-0.19 Consensus Rating Strong Buy Average Move 5.80% Can Allogene's Cash Runway Outlast...

ALLO : 2.00 (+2.04%)
Allogene Therapeutics to Report First Quarter Financial Results and Provide Business Update

Conference Call and Webcast Scheduled for May 13, 2026 at 2 p.m. PT/5 p.m. ET SOUTH SAN FRANCISCO, Calif., May 06, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage...

ALLO : 2.00 (+2.04%)
Allogene Therapeutics Expands Pivotal Phase 2 ALPHA3 Trial to South Korea and Australia

Expansion Adds to Growing Global Trial Footprint Patient Screening and Enrollment Expected to Begin in Q2 2026 SOUTH SAN FRANCISCO, Calif., April 21, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics,...

ALLO : 2.00 (+2.04%)
Allogene Therapeutics Showcases Momentum with Clinical and Platform Advancements in Allogeneic CAR T at AACR 2026

SOUTH SAN FRANCISCO, Calif., April 20, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR...

ALLO : 2.00 (+2.04%)
Allogene Therapeutics Announces Closing of $200.4 Million Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., April 16, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the closing of its previously announced underwritten public offering of 87,500,000...

ALLO : 2.00 (+2.04%)
Allogene Therapeutics Announces Nature Communications Publication Highlighting Pre-Clinical Data for ALLO-329, a Next Generation Dual-Targeted CD19/CD70 Allogeneic CAR T for Autoimmune Diseases

Study Highlights Dagger ® Technology Showing that an Optimized CD70 CAR has the Potential to Protect Against Immune Rejection, Enabling Robust Expansion and Persistence of Allogeneic CAR T Cells in...

ALLO : 2.00 (+2.04%)
Allogene Therapeutics Announces Pricing of Public Offering of Common Stock

SOUTH SAN FRANCISCO, Calif., April 14, 2026 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO) today announced the pricing of an underwritten public offering of 87,500,000 shares of its common...

ALLO : 2.00 (+2.04%)

Business Summary

Allogene Therapeutics, Inc. is a clinical-stage immuno-oncology company, primarily focused on the development and commercialization of genetically engineered allogeneic T cell therapies for the treatment of cancer.'

See More

Key Turning Points

3rd Resistance Point 2.14
2nd Resistance Point 2.10
1st Resistance Point 2.05
Last Price 2.00
1st Support Level 1.95
2nd Support Level 1.91
3rd Support Level 1.86

See More

52-Week High 4.46
Fibonacci 61.8% 3.13
Fibonacci 50% 2.72
Fibonacci 38.2% 2.31
Last Price 2.00
52-Week Low 0.98

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.